Alzheimer's disease is a neurodegenerative condition that typically develops gradually and gets worse over time. It is a form of dementia that progresses over time, causing a person's capacity for independent functioning to be disrupted by a steady decline in thinking, behavioural, and social abilities. Alzheimer's disease has no known cure, but there are treatments that may slow down the disease's progression as well as medication and non-medication options that could help manage symptoms.
Global Alzheimer’s disease diagnostics and therapeutics market is estimated to be valued at US$ 6,231.1million in 2022 and is expected to exhibit a CAGR of 5.4% during the forecast period (2022-2030).
Figure 1. Global Alzheimer’s disease Diagnostics and Therapeutics Market Share (%), By Product, 2022
Global Alzheimer’s disease Diagnostics and Therapeutics Market- Drivers
Increase in the prevalence of Alzheimer’s disease in the old age population is expected to drive the market for the forecast period.
According to Alzheimer's Association, April 2022, an estimated 6.5 million people age 65 and older in 2021 were living with Alzheimer's in the U.S. among which 73% were aged 75 or older.
Key players are focusing on providing new diagnostic tests which will drive the market growth during the forecast period. For instance, Attyloid GmbH, a biotechnology company, offers a biomarker-based laboratory test sFIDA (surface-based fluorescence intensity distribution analysis), for diagnosing Alzheimer’s disease. sFIDA can identify and quantify Aβ oligomers. These small protein aggregates play a significant role in the development and prognosis of Alzheimer’s disease. By sFIDA, differentiation between control samples and AD patient is easily possible.
Report Coverage | Details | ||
---|---|---|---|
Base Year: | 2021 | Market Size in 2022: | US$ 6,231.1 Mn |
Historical Data for: | 2017 to 2020 | Forecast Period: | 2022 to 2030 |
Forecast Period 2022 to 2030 CAGR: | 5.4 % | 2030 Value Projection: | US$ 9,503.1 Mn |
Geographies covered: |
|
||
Segments covered: |
|
||
Companies covered: |
Luye Pharma Group, Vigil Neuroscience, Inc., Grifols, S.A., AbbVie Inc., Zydus Lifesciences Ltd., Merck KGaA, F. Hoffmann-La Roche Ltd., Novartis AG, Johnson & Johnson, Eli Lilly and Company, Biogen Inc., Siemens Healthcare GmbH, Merz Pharma, Eisai Co. Ltd., Lupin Limited, Teva Pharmaceutical Industries Ltd., Apotex Inc., Corium, Inc., Supernus Pharmaceuticals, Inc. |
||
Growth Drivers: |
|
||
Restraints & Challenges: |
|
Figure 2. Global Alzheimer’s disease Diagnostics and Therapeutics Market Share (%), by Region, 2022
Global Alzheimer’s disease Diagnostics and Therapeutics Market– Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.
COVID-19 has affected the economy in three main ways: by directly affecting production and demand of drugs and vaccines, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, U.A.E., Egypt, and others, faced problems with regard to the transportation of drugs and vaccines from one place to another.
The rising cases of COVID-19 are expected to have a short-term negative impact on diagnostic rates of Alzheimer's disease. The short-term effects on the market are less prominent; however, the adverse impacts of COVID-19 on the global economy can have significant effects on the market.
Global Alzheimer’s disease Diagnostics and Therapeutics Market: Key Developments
In October 2021, Salk Institute, a research institute in California, U.S., initiated a phase 1 clinical trial of the investigational Alzheimer’s drug CMS121 to evaluate its safety in humans.
Moreover, In June, 2021, Biogen, a multinational biotechnology company, and Eisai Inc., a U.S. subsidiary of Eisai Co., Ltd., announced a range of programs/initiatives intended to support access for all qualified patients, including traditionally underserved populations
Global Alzheimer’s disease Diagnostics and Therapeutics Market: Restraint
The uncertainty, failure, and discontinuation of the clinical trials of Alzheimer's drugs lead to the availability of limited treatment alternatives. This increases the costs related to research and development. Hence, it is expected to restrain the market growth. For instance, Amgen Inc. and Novartis AG discontinued their Phase 2 clinical trial for CNP520 (umibecestat), a BACE1 inhibitor for Alzheimer's disease, in July 2019, due to the lack of desired results.
Global Alzheimer’s disease Diagnostics and Therapeutics Market- Key Players
Major players operating in the global Alzheimer’s disease diagnostics and therapeutics market include Luye Pharma Group, Vigil Neuroscience, Inc., Grifols, S.A., AbbVie Inc., Zydus Lifesciences Ltd., Merck KGaA, F. Hoffmann-La Roche Ltd., Novartis AG, Johnson & Johnson, Eli Lilly and Company, Biogen Inc., Siemens Healthcare GmbH, Merz Pharma, Eisai Co. Ltd., Lupin Limited, Teva Pharmaceutical Industries Ltd., Apotex Inc., Corium, Inc., Supernus Pharmaceuticals, Inc.
Alzheimer’s disease is a neurodegenerative disease that usually starts slowly and progressively worsens. It is a progressive form of dementia, a continuous decline in thinking, behavioral, and social skills that disrupts a person's ability to function independently. Doctors perform a series of tests to rule out other possible causes of impairment. It can be diagnosed in several different ways. Imaging techniques, such as CT and MRI, are primarily used to rule out other conditions that may cause symptoms similar to Alzheimer's but require different treatment. There's no cure for Alzheimer's disease, but there are treatments that may change disease progression, and drug and non-drug options that may help treat symptoms. Aducanumab is the only disease-modifying medication currently approved to treat Alzheimer's. Medications may temporarily improve or slow progression of symptoms. These treatments can sometimes help people with Alzheimer's disease maximize function and maintain independence for a time. In advanced stages of the disease, complications from severe loss of brain function — such as dehydration, malnutrition or infection — result in death.
Market Dynamics
Increasing use of biomarkers in Alzheimer’s diagnosis and drug development and increasing focus on the development of novel diagnostics & therapeutics due to increase in disease burden is expected to boost the growth of the global Alzheimer’s disease diagnostics and therapeutics market. For instance, in June 2021, the Alzheimer’s Drug Discovery Foundation (ADDF) Diagnostics Accelerator launched four new research investments for the development of digital biomarkers for Alzheimer's diagnosis. Moreover, in August 2022, the Alzheimer's Association announced the launch of Alzheimer's Network for Treatment and Diagnostics (ALZ-NET), a platform to collect long-term clinical and safety data from patients treated with U.S FDA-approved Alzheimer's disease therapies in real world clinical settings. It is the first network developed specifically for FDA-approved Alzheimer's treatments, collecting real-world evidence on drug effectiveness and side effects over a long period of time.
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients